

**Connective Tissue Oncology Society Liddy  
Shriver Early Career Research Award  
Nomination Guidelines**

**Nominator**

Name

E-mail Address

Phone

Date Submitted

Signature

**Nominee**

Name

Nationality

**First Faculty Appointment**

Institution and Country

Position

Date

**Current Faculty Appointment**

Institution and Country

Position

Date

E-mail Address

Phone

**In order for a nominee to be considered for this award, the Nomination Packet which is sent to CTOS must be received by June 1, 2018 and **must include:****

1. Dated and signed nomination letter (up to five pages in length) submitted on the nominator's institution's stationary
2. Dated and signed letters of support (up to five pages in length) from at least two other sarcoma researchers submitted on each researcher's institution's stationary. At least one of these letters must come from a researcher outside the nominee's institute.
3. The Nominee's NIH Bio-Sketch
4. The Letter of Nomination Compliance (see page 3)
5. The Letter of Financial Compliance (see page 4)
6. Other materials the nominator wishes the Award Panel to consider. The relevance of this material should be explained in the nominator's nomination letter or the letters of support.

**The Nomination Letter and Letters of Support Should Address at least the Following Issues**

*The Award is intended to recognize an outstanding early-career researcher working in the sarcoma field. It is not primarily an award for future research, but an award based on track record of early achievement.*

Why do you consider the nominee to be an "outstanding early-career researcher" – e.g. are there particular papers in which results attributed to the nominee have been characterized as important, new insights into one or more fundamental issue about sarcoma? What are the insights and what are the issues?

*The award will be made on the basis of internationally recognized, outstanding contributions by the researcher to the field of sarcoma research.*

What are some of the nominee's "internationally recognized, outstanding contributions"?

Can you cite instances of researchers in various countries citing and using some of the nominee's results in their own work?

Has the nominee developed any new, important laboratory methods or techniques that are now used in sarcoma research?

Has the nominee been involved in any collaborative research projects that have yielded important results. If so, what role did the nominee play in these projects?

*Nominees must demonstrate a focus specifically on research into sarcomas.*

Does the nominee spend more than 50% of his/her time in sarcoma related research? If so, which subtypes of sarcoma.

*Additional Insights*

What additional insights would you like to share about your nominee's early career research contributions?



ctos

Bringing together the  
world's sarcoma specialists



a global initiative

*for everyone affected by sarcomas*

**Letter of Nomination Compliance**  
**To be sent on the Nominee's Institution's Stationary**

<Date>

Chair, CTOS LSERA Panel  
<address provided by CTOS>

Dear <NAME OF CHAIR>,

I am honored to learn that <NAME OF NOMINATOR> is nominating me to be considered for the CTOS Liddy Shriver Early Career Research Award. <HE/SHE> has also informed me about the following conditions associated with this award:

1. The CTOS LSERA Award recipient will receive US\$50,000, to go to research into sarcomas. The guidelines for the use of the funds are subject to the usual conditions of grants from the Liddy Shriver Sarcoma Initiative, i.e. the funds are to be used only to directly support research and not administrative costs, travel fees, conference fees, or publications costs.
2. The CTOS LSERA Award recipient must give a lecture at the CTOS annual meeting. The talk will be at least 30 minutes in duration.
  - i. The lecture should project forward in time, reflecting the awardee's anticipated future research in the field of sarcoma.
  - ii. The lecture must be submitted as an essay of between 1800 and 3000 words in PDF format, to the CTOS website for public access.
3. Funding support from the CTOS Liddy Shriver Early Career Research Award will be acknowledged in all publications in which results from this research study are presented.

If I am selected to receive this award, I hereby indicate that I will comply with these conditions.

Sincerely,

<NOMINEE'S SIGNATURE>  
<NOMINEES NAME>

**CC:**  
<NAME OF NOMINATOR>  
Liddy Shriver Sarcoma Initiative

**Letter of Financial Compliance**  
**To be sent on the Nominee's Institution's Stationary**

<Date>

Bruce D. Shriver, PhD  
Director, Research Grants Program  
Liddy Shriver Sarcoma Initiative  
17 Bethea Drive  
Ossining, NY 10562

Dear Bruce,

I am pleased to learn that <NAME OF NOMINEE> from our institution has been nominated to be considered for the CTOS Liddy Shriver Early Career Research Award. I understand that if < NAME OF NOMINEE > receives this award that <HE/SHE> will be awarded \$50,000 to focus on <HIS?HER> sarcoma research. If < NAME OF NOMINEE> receives this award, we agree that none of the funds awarded will be used to support the salary of the investigator or the facilities and administrative costs of our institution. Furthermore, none of the funds will be used to support travel, publication costs or conference and workshop-related fees.

Sincerely,

Financial Officer's Signature

Financial Officer's Name (print) \_\_\_\_\_

Financial Officer's Title \_\_\_\_\_

**CC:**

CTOS Executive Director  
<NAME OF NOMINEE>  
<NAME OF NOMINATOR>